MISSISSAUGA, Ontario--(BUSINESS WIRE)--Apr. 26, 2018--
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an
advanced medical technologies company, today announced that two clinical
case studies demonstrating the clinical effectiveness of ColActive®
Plus and ColActive® Transfer biological matrix products will
be presented at the 2018 Symposium on Advanced Wound Care Spring (“SAWC
Spring”) in Charlotte, North Carolina. In addition to the posters,
Covalon will also be showcasing its full line of advanced wound care
dressings in the symposium’s exhibition hall during the three-day event.
“We are very pleased with the results of these two clinical case studies
and believe that they show the advantage that the patented ColActive
technology can add to a wound care clinician’s arsenal,” said Brian
Pedlar, Chief Executive Office of Covalon.
Dr. Jeffrey Lehrman, DPM, FASPS, MAPWCA will present a clinical poster
entitled A New Approach in the Management of Chronic Diabetic Foot
Ulcers: A Report on the Use of a Collagen Wound Contact Layer with
Negative Pressure Wound Therapy during the SAWC Spring – WHS Poster
Gala, held on Friday, April 27th from 7:15 p.m. to 8:45 p.m.
“The combination of a collagen wound contact layer and weekly negative
pressure wound therapy had a significant beneficial effect on healing in
this chronic diabetic foot ulcer,” said Dr. Lehrman. “The regimen was
well tolerated and simple to administer and offers a valuable
opportunity for healing in this patient group.”
Also being presented at the SAWC Spring – WHS Poster Gala is a clinical
case series entitled A New Approach in the Treatment of Chronic
Pressure Ulcers at our Center: A Report on the Use of Collagen in Saudi
Arabia by Abdulkareem Iblasi, RN, MSN, and Manju Paulose of King
Saud Medical City in Riyadh, Saudi Arabia.
SAWC is the Official Meeting for Members of The Association for the
Advancement of Wound Care and the leading national wound healing
conference SAWC Spring serves as a forum to connect the entire wound
care team — physicians, nurses, physical therapists, researchers,
scientists, podiatrists, and dietitians — with the foremost experts in
wound care to improve patient outcomes through education. No other wound
care conference offers the level of education, advanced state-of-the-art
clinical reviews and emerging research findings. The conference runs
from April 26-28, 2017, and Covalon will be exhibiting in booth #1311
during all exhibit hours throughout the meeting.
Covalon offers unique, patent protected infection management and
advanced wound management solutions for the wound clinician. Covalon’s
CovaWound™ and ColActive® brands when used
together have the ability to rapidly promote wound closure and healing
in both acute and chronic wounds.
Covalon Technologies Ltd. researches, develops
and commercializes new healthcare technologies that help save lives
around the world. Covalon's patented technologies, products and services
address the advanced healthcare needs of medical device companies,
healthcare providers and individual consumers. Covalon's technologies
are used to prevent, detect and manage medical conditions in specialty
areas such as wound care, tissue repair, infection control, disease
management, medical device coatings and biocompatibility. To learn more
about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect
the Company's current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as "seek", "anticipate", "plan, "estimate", "expect",
"intend" and statements that an event or result "may", "will", "should",
"could" or "might" occur or be achieved and other similar expressions.
These forward-looking statements involve risk and uncertainties,
including the difficulty in predicting product approvals, acceptance of
and demands for new products, the impact of the products and pricing
strategies of competitors, delays in developing and launching new
products, the regulatory environment, fluctuations in operating results
and other risks, any of which could cause results, performance, or
achievements to differ materially from the results discussed or implied
in the forward-looking statements. Many risks are inherent in the
industry; others are more specific to the Company. Investors should
consult the Company's ongoing quarterly filings for additional
information on risks and uncertainties relating to these forward-looking
statements. Investors should not place undue reliance on any
forward-looking statements. The Company assumes no obligation to update
or alter any forward-looking statements whether as a result of new
information, further events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180426006036/en/
Source: Covalon Technologies Ltd.
Covalon Technologies Ltd.
Brian Pedlar, 905-568-8400 x 233
Web site: www.covalon.com